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Bone marrow-derived mesenchymal stromal cell- (BM-MSC-) based therapy is a promising option for regenerative medicine. An
important role in the control of the processes influencing the BM-MSC therapeutic efficacy, namely, extracellular matrix
remodelling and proliferation and secretion ability, is played by matrix metalloproteinase- (MMP-) 2. Therefore, the identification
of paracrine/autocrine regulators of MMP-2 function may be of great relevance for improving BM-MSC therapeutic potential.
We recently reported that BM-MSCs release the bioactive lipid sphingosine 1-phosphate (S1P) and, here, we demonstrated an
impairment of MMP-2 expression/release when the S1P receptor subtype S1PR1 is blocked. Notably, active S1PR1/MMP-2
signalling is required for F-actin structure assembly (lamellipodia, microspikes, and stress fibers) and, in turn, cell
proliferation. Moreover, in experimental conditions resembling the damaged/regenerating tissue microenvironment (hypoxia),
S1P/S1PR1 system is also required for HIF-1α expression and vinculin reduction. Our findings demonstrate for the first time
the trophic role of S1P/S1PR1 signalling in maintaining BM-MSCs’ ability to modulate MMP-2 function, necessary for
cytoskeleton reorganization and cell proliferation in both normoxia and hypoxia. Altogether, these data provide new
perspectives for considering S1P/S1PR1 signalling a pharmacological target to preserve BM-MSC properties and to potentiate
their beneficial potential in tissue repair.
This paper is dedicated to the dear memory of Lucia Formigli who has passed away on March 18, 2014
1. Introduction
Mesenchymal stromal cells (MSCs) are adult stem cells,
found in situ within all adult mammalian supportive stro-
mal tissue compartments, where they play a key role in
the organization and maintenance of tissue integrity and
in the physiological/pathological tissue repair [1]. How-
ever, their main source remains the bone marrow, where
they were originally identified [2]. Ex vivo expanded adult
bone marrow-derived MSCs (BM-MSCs) have long been
viewed as a potent tool for cell therapy and regenerative
medicine [1, 3, 4]; their effectiveness has been proven in
many preclinical in vitro and in vivo studies and clinical trials
are currently ongoing [3, 5–11].
It has been observed that the efficacy of BM-MSCs in
terms of tissue repair/regeneration is mainly dependent on
several properties, such as the ability of these cells to (i)
migrate through the extracellular matrix (ECM) where they
reside, (ii) transmigrate through the endothelial cell layer
and the underlying basement membrane when ex vivo
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expanded and systemically administered, (iii) reach the site
of injury, and (iv) survive and proliferate in the damaged tis-
sue, where they secrete a broad range of factors (secretome)
with multiple beneficial effects [3, 11–14]. Tissue-specific dif-
ferentiation of transplanted BM-MSCs still remains an issue
of debate. For most of these biological processes, ECM repre-
sents a key factor tightly interplaying with BM-MSCs.
Indeed, structural and molecular changes in ECM composi-
tion and interactions between ECM components and the cell
itself can trigger intracellular signalling pathways involved in
the control of different cell processes, such as cytoskeletal
rearrangement, spreading, survival, proliferation, and migra-
tion [15–17]. ECM composition and remodelling depend in
part on the activity of proteolytic enzymes that selectively
digest individual components of the matrix, matrix metallo-
proteinases (MMPs), which are constitutively expressed by
a wide range of cell types, including BM-MSCs, MSCs
from adipose tissue and from other tissues [14, 18–21].
Studies aimed at elucidating BM-MSC-secreted molecules,
as well as their downstream signalling pathways, are
remarkably increasing in recent years [3, 4, 12, 13, 22].
By contrast, the factors and the molecular mechanisms
possibly involved in the modulation of BM-MSC secretome
in the tissue microenvironment are far from being elucidated.
Therefore, the identification of modulators of BM-MSC
secretome with autocrine/paracrine actions could be of great
biological relevance for improving the therapeutic/beneficial
potential of BM-MSCs. Among these modulatory factors,
sphingosine 1-phosphate (S1P) could represent a good
candidate. S1P belongs to the large family of bioactive sphin-
golipids, membrane-derived lipid mediators which are gen-
erated from phospholipid membrane precursors [23–25].
The major sources of S1P are represented by activated plate-
lets and by cells subjected to a various degree of damage or
stimulation by different growth factors, thus suggesting a
potential role for the sphingolipid in many physiological
and pathological conditions [17, 25–31]. We have recently
demonstrated that BM-MSCs are also able to produce S1P
through sphingosine kinase (SphK) activation and to release
it similarly to many other cell types [32]. S1P is a peculiar
bioactive lipid: it acts as an intracellular mediator as well as
a ligand for multiple G protein-coupled membrane receptors,
a class of proteins belonging to the endothelial differentiation
gene (Edg) family, currently named S1PR1-5 [25, 29]. The
binding of S1P to S1PR subtypes leads to their differential
coupling to heterotrimeric G-proteins and downstream effec-
tor targets, thereby promoting specific cellular responses,
including migration, adhesion, survival, proliferation, and
gene expression in many cell types, including stem cells
[17, 25–27, 31, 33–42]. Since S1PR subtypes differ in their
tissue distribution, the specific effect of S1P is determined,
at least in part, by the predominance of the expressed recep-
tor subtypes [25, 29, 31]. The therapeutic options related to
S1P/S1PR signalling are numerous as demonstrated by sev-
eral clinical trials [31] and the recent approval by the Food
and Drug Administration and the European Medicines
Agency of FTY720 (Fingolimod, Gilenya, Novartis) for the
treatment of relapsing multiple sclerosis [43, 44], acting as
functional S1PR1 antagonist [45].
Although the multiple functions of S1P/S1PR signalling
in many cell types, the involvement of S1PR subtypes on
the autocrine/paracrine action of BM-MSCs remains elusive.
On these bases, the aim of this study was to evaluate whether
S1P/S1PR-mediated signalling could affect the ability of BM-
MSCs to express and release MMP-2, the main MMP iso-
form/collagenase [14, 46, 47], whose expression and activity
have been demonstrated to be regulated by S1P in many cell
types [34, 48, 49] and, in parallel, to affect cytoskeletal orga-
nization and cell proliferation.
The experiments were conducted in cells cultured
either in normoxic and hypoxic conditions in order to
mimic the microenvironment occurring in a damaged/
regenerating tissue.
2. Materials and Methods
2.1. Cell Culture and Treatments. Mouse bone marrow
mesenchymal stromal cells (BM-MSCs) were isolated from
the femura and tibiae of male C2F1 mice, expanded
in vitro, characterized, and cultured as reported previously
[6]..The cells were plated at low- (3–5,000 cells cm−2) and
high- (15–20,000 cells cm−2) density confluence and treated
for 48h with specific vehicle or with the following com-
pounds: sphingosine kinase inhibitor (iSK, 5μM, Tocris Bio-
science, Bristol, UK) [30, 32, 50]; sphingosine 1-phosphate
(S1P, 1μM, Calbiochem, San Diego, CA, USA, stock solution
2mM in DMSO) S1PR1 receptor antagonist, W146 (2μM,
Tocris Bioscience, stock solution 2mM in DMSO) [51],
S1PR1 receptor agonist, SEW2871 (2μM, Tocris Bioscience,
stock solution 2mM in DMSO) [52], MMP-2, and MMP-9
inhibitor, SB-3CT (5 and 10μM, Sigma, Milan, Italy, stock
solution 10mM in DMSO) [32]. DMSO less than 0.1% has
been used as a vehicle.
In parallel experiments in order to mimic the hypoxic
conditions occuring in damaged/regenerating tissue, the cells
were cultured in a hypoxic chamber by lowering the oxygen
concentration to 2% for 48h in the absence (vehicle) or pres-
ence of W146 or SEW2871.
2.2. Gelatinase Assay. The MMP activity in BM-MSCs was
evaluated using EnzChek® Gelatinase/Collagenase Assay
Kit (Molecular Probes, Eugene, OR, USA) which provides a
highly quenched, fluorescein-labeled gelatin (DQ™ gelatin),
essentially as previously reported [8]. Upon proteolytic diges-
tion, the green fluorescence of the gelatin is revealed and can
be used to measure enzymatic activity. In particular, the wells
of a 96-well microplate reader were coated with 25μg ml−1 of
DQ gelatin following the manufacturer’s instructions; the
cells were added to the coated wells and cultured in normoxic
conditions in the absence or presence of specific compounds
for 24–48 h before reading the fluorescent intensity by using a
multiwell scanning spectrophotometer (ELISA reader;
Amersham, Pharmacia Biotech, Cambridge, UK) at a wave-
length of 515nm.
In parallel experiments, the cells were seeded onto glass
coverslips previously coated with fluorescein-conjugated
DQ gelatin (25μg ml−1), cultured as above and then observed
2 Stem Cells International
under a confocal Leica TCS SP5 microscope (Leica Microsys-
tems, Mannheim, Germany).
2.3. Reverse Transcription (RT) and Endpoint PCR Analysis.
The expression levels of mRNA for S1P receptor subtypes
(S1PR) in BM-MSCs at different cell density were deter-
mined by RT-PCR as reported previously [17]. In particular,
total RNA was purified with TRI REAGENT (Sigma),
according to the manufacturer’s instructions. Concentration
and purity of extracted total RNA were evaluated by
measuring the absorbance at 260 and 280nm wavelength
and the absence of degradation confirmed by agarose gel
electrophoresis with ethidium bromide staining. One μg of
total RNA from BM-MSCs was reverse-transcribed to a
single-stranded cDNA using the commercially available
cDNA Synthesis Kit (SuperScript® III cells Direct cDNA
Synthesis Kit; Thermo Fisher Scientific, Waltham, MA,
USA) according to the manufacturer’s instructions. Mouse
C2C12 cells, which constitutively express S1PR1, S1PR2,
and S1PR3 [33], were used as positive controls (data not
shown). Samples were incubated at 25°C for 5min, at 42°C
for 50min, and then at 70°C for 5min in a thermal cycler
(Perkin Elmer, Monza, Italy).
We designed the following forward and reverse primers:
S1PR1 (NM_007901), forward 5′-CCG CAA GAA CAT
CTC CAA GG-3′ (710–731 bp), reverse 5′-GGC AAT GAA
GAC ACT CAG GA-3′ (781–801 bp) (transcript length
91 bp); S1PR2 (NM_010333), forward 5′-CAT CGT GGT
GGA GAA TCT TCT G-3′ (137–159 bp), reverse 5′-CAG
GTTGCCAAGGAACAGGTA-3′ (204–225 bp) (transcript
length 88 bp); S1PR3 (NM_007901), forward 5’-CCA CCT
GCA GCT TAC TGG CC-3′ (376–396 bp), reverse 5′-GGC
AAT TAG CCA GCA CAT CCC-3′ (477–498) (transcript
length 122 bp); S1PR4 (NM_010102.2), forward 5′-GGA
CTT CTC GGT CAC TCA GC-3′(1089–1109 bp) reverse
5′-GGC TTG CTG TCA TGT TCT CA-3′ (1236–1256 bp)
(transcript length 167 bp); S1PR5 (NM_053190.2), forward
5′-GGA GGG ACT CTC CTG GAT TC-3′ (1580–
1600 bp), reverse 5′-TTC CTC TGT AGC CAG CCA CT-
3′ (1744–1764 bp) (transcript length 184 bp); GAPDH
(XR_002379299.1), forward 5′-GGT GCT GAG TAT GTC
GTG GA-3′ (342–362 bp), and reverse 5′-CCT TCC ACA
ATG CCA AAG TT-3′ (483–503 bp) (transcript length
161 bp).
2.4. Real-Time PCR. Quantitative real-time PCR was carried
out using the Rotor Gene 6000 (Corbett Research, Corbett
Life Science, Concorde, NSW 2137, Australia) and Syber
Green reagents (Life Technologies), consisting in a specific
set of primers (200 nM) and a fluorogenic internal probe.
The expression of S1PR genes was quantitated in comparison
with the housekeeping gene GAPDH [17]. PCR amplifica-
tions were performed on cDNA samples corresponding to a
final RNA concentration of 50 ng. PCR was performed in a
total volume of 25μl containing 2×PCR Master mix (Life
Technologies). Reaction conditions were as follows: 95°C
for 10min, followed by 35–40 cycles at 95°C for 15 s
alternating with 52°C or 55°C or 60°C for 1min and 72°C
for 45 s. PCR amplifications were run in duplicates. Blank
controls were performed in each run.
For the evaluation of S1PR4 and S1PR5 mRNA expres-
sion, double amount of cDNA (4μl) was used and 40 cycles
of amplification performed. The results of the real-time
PCR were determined as Ct values, where Ct was defined
as the PCR threshold cycle at which amplified product was
first detected. All values were normalized to the GAPDH
housekeeping gene expression and ∆Ct calculated [17].
The ratio between the fold of variation of S1P receptor
expression obtained from high- and low-density BM-MSCs
culture is reported.
2.5. Confocal Laser Scanning Microscope Analysis. Immu-
nofluorescence analyses on fixed BM-MSCs were per-
formed essentially as reported previously [6]. BM-MSCs
grown on glass coverslips were fixed with 0.5% buffered
paraformaldehyde (PFA) for 10min at room temperature.
After permeabilization with cold acetone for 3min, the
fixed cells were blocked with 0.5% bovine serum albumin
(BSA; Sigma) and 3% glycerol in PBS for 20min and then
incubated overnight at 4°C, with the following primary
antibodies: rabbit polyclonal anti-Ki67 (1 : 100; Abcam,
Cambridge, UK), rabbit polyclonal anti-MMP-2 (1 : 200;
Abcam), rabbit polyclonal anti-cortactin (1 : 50; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal
anti hypoxia-inducible factor-1α (HIF-1α; 1 : 100; Santa Cruz
Biotechnology), and mouse monoclonal anti-vinculin
(1 : 100; Sigma).
The immunoreactions were revealed by anti-rabbit Alexa
Fluor 488-conjugated IgG (1 : 200; Molecular Probes) or anti-
mouse Cy5-conjugated IgG. Actin filament organization was
evaluated by labeling the cells with Alexa 568-labelled phal-
loidin (1 : 100; Molecular Probes). In some experiments,
nuclei were counterstained with propidium iodide (PI,
1 : 30; Molecular Probes). Negative controls were carried
out by replacing the primary antibodies with non-immune
serum; cross-reactivity of the secondary antibodies was tested
in control experiments in which primary antibodies were
omitted. The coverslips containing the immunolabelled cells
were observed under a confocal Leica TCS SP5 microscope
(Leica Microsystems) equipped with a HeNe/Ar laser source
for fluorescence measurements and with differential interfer-
ence contrast (DIC) optics. Observations were performed
using a Leica Plan Apo 63X/1.43NA oil immersion objective.
Series of optical sections (1024× 1024 pixels each; pixel size
204.3 nm) 0.4μm in thickness were taken through the depth
of the cells at intervals of 0.4μm. Images were then projected
onto a single “extended focus” image. Ki67 positive nuclei
were evaluated in 10 random 200× 200μm2 microscopic
fields (63×objective) in each cell preparation and expressed
as percentage of the total cell nuclei.
Densitometric analyses of the intensity of MMP-2, HIF-
1α, and vinculin fluorescent signals were performed on digi-
tized images using ImageJ software (http://rsbweb.nih.gov/ij)
in 20 regions of interest (ROI) of 100μm2 for each confocal
stacks (at least 10). Colocalization analysis of cortactin and
F-actin fluorescent signals was performed using ImageJ
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JACOP plugin [53] and the colocalization parameter, overlap
coefficient, was reported.
2.6. Gelatin Zymography. MMP-2/collagenases activity was
assessed by gelatin zymography by using conditioned
medium obtained from BM-MSCs essentially as previously
reported [17]. After 48 h of cell culture, the conditioned
medium of BM-MSCs treated with W146 or SEW2871
or vehicle was collected and centrifuged at 10,000g for
15min and stored at −20°C. Samples, 20–25μl each, were
mixed with sample buffer and separated on 10% SDS-
polyacrylamide gels containing gelatin (1mg ml−1), and
the gel was developed. The MMPs appear as bright bands
within the stained gel corresponding to the position of
active MMP-2.
2.7. Western Blotting Analysis. Cells were lysed in hypotonic
medium (about 23mM compared with 137mM in isotonic
medium) using a Dounce homogenizer, and nuclear fraction
was obtained by centrifugation at 1,000g at 4°C. Proteins
(20–30μg) from lysates were subjected to electrophoresis
(SDS-PAGE) and Western blotting analysis was performed
as previously described [17, 30, 32]. To immunodetect
endogenous HIF, rabbit polyclonal antibody against HIF-1α
(1 : 1000; 132 KDa; Santa Cruz Biotechnology) was utilized.
Rabbit polyclonal antibody anti-Bax (1 : 500; 21 KDa; Santa
Cruz Biotechnology) and rabbit polyclonal antibody anti-
Beclin (1 : 500; 52 KDa; Cell Signalling Technology, Danvers,
MA, USA) were used to detect the proapoptotic and the
autophagy markers, respectively. Bound antibodies were
revealed by anti-rabbit immunoglobulin G1 conjugated to
horseradish peroxidase (Santa Cruz Biotechnology) and
ECL reagents (Amersham Pharmacia Biotech, Italy). Anti
β-actin (1 : 10,000; 42 KDa; Santa Cruz Biotechnology)
was used to demonstrate the quality and equivalent load-
ing of protein.
2.8. Cell Proliferation and Viability Analyses. BM-MSCs were
incubated for 24 h in DMEM containing 10% FBS (Sigma) in
the absence or in the presence of compounds as reported in
the indicated experiments. Cells were counted after fixation
and propidium iodide staining by TALI® cytometry (Life
Technologies). Cell proliferation was evaluated also by
Ki67 confocal immunofluorescence analysis as previously
reported [32]. Cell viability was evaluated by nonradioactive
cell assay (MTT) (CellTiter 96® Assay; Promega Corpora-
tion, Madison, WI, USA), according to the manufacturer’s
protocol and as reported previously [30, 32].
2.9. Statistical Analysis. Data were reported as mean± S.E.M.
Statistical significance was determined by one-way ANOVA
and Newman-Keuls multiple comparison test or Student’s
t-test. A p value≤ 0.05 was considered significant. Calcula-
tions were performed using GraphPad Prism software
(GraphPad, San Diego, CA, USA).
3. Results
3.1. BM-MSC Gelatinolytic Activity Is Regulated by S1P/
S1PR1 Axis. Owing to previous data demonstrating that
BM-MSCs produce and release S1P [32], we evaluated the
ability of the bioactive lipid to exert an autocrine action
through the activation of S1P receptor-mediated signalling.
First, we analysed by reverse transcription and real-time
PCR the expression of the five S1P receptor (S1PR) subtypes
and we found that BM-MSCs expressed three of five S1PRs,
S1PR1, S1PR2, and S1PR3 (Figures 1(a) and 1(b)), whereas
in this experimental conditions, S1PR4 and S1PR5 subtypes
were not detectable. However, bands corresponding to
S1PR4 and S1PR5 were detected when the real-time PCR
amplification was performed by using double amount of
cDNA (Figures 1(c) and 1(d)).
Next, we compared the expression profile of these S1PR
subtypes in low-density and high-density BM-MSC cultures.
This is because changes in the cell behavior occur when
MSCs, recruited to the injury site in pathological conditions,
start accumulating in the damaged area. Indeed, from scat-
tered cells, they become a conspicuous pool of cells. As
shown in (Figures 1(a) and 1(b)), in high-density cell culture
conditions, the real-time PCR analysis indicated that S1PR1
displayed a marked increase, S1PR3 a slight one, whereas
S1PR2 did not change, suggesting a prevalent role of S1PR1
in the high-density pool of BM-MSCs.
Based on these data, we focused our further investiga-
tions on the involvement of S1PR1 on the control of the
secretion and activity of MMPs in high-density cell culture.
Cells were first treated with a selective SphK inhibitor (iSK,
5μM), that blocks S1P synthesis, in order to evaluate the con-
tribution of S1P inside-out signalling or with exogenous S1P
(exoS1P, 1μM).
By the fluorescent gelatin degradation assay, we found
that the ability of BM-MSCs to synthesize functional
gelatinases was remarkably reduced when the cells were
cultured in the presence of iSK (Figures 1(e) and 1(f)),
indicating that S1P production is required for this
function. Moreover, gelatin degradation appears to be
slightly increased after stimulation with exoS1P (Figures 1(e)
and 1(f)), further confirming that S1P/S1PR-mediated
signalling plays a role in the autocrine control of MMP
functionality in BM-MSCs. Moreover, we found that the
cells in the presence of S1PR1 receptor antagonist, W146
(2μM), dramatically reduced their cell gelatinolytic activity
(Figures 1(e) and 1(f)), without showing any particular mor-
phological features of cell suffering, as indicated in DIC
images (Figure 1(f)).
The addition of SEW2871 (2μM), a specific S1PR1
agonist, did not promote any effect as compared to control
(Figures 1(e) and 1(f)), thus suggesting a potential constitu-
tive activation of S1PR1-signalling by S1P physiologically
produced inside the cells and released into the medium.
Interestingly, these data point out that S1P/S1PR1
system is required for maintaining the gelatinolytic abil-
ity of BM-MSCs.
3.2. S1PR1 Is Required for MMP-2 Expression/Activity in BM-
MSCs. Successively, we examined the role of S1P/S1PR1 axis
in the control of MMP-2 expression/activity in BM-MSCs.
According to the results of gelatin degradation assay, confo-
cal immunofluorescence analysis revealed that the cells
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Figure 1: S1P receptor subtype expression and SphK/S1PR axis role in cell gelatinolytic activity. (a and c) Expression of S1P receptors by
reverse transcription (RT) and real-time PCR analysis. mRNA were determined by RT of total RNA (1 μg) obtained from BM-MSCs at
low- (L-) and high- (H-) density culture and 2μl of cDNA (for S1PR1, S1PR2, and S1PR3 detection) or 4μl of cDNA (for S1PR4 and
S1PR5 detection) were amplified as described in Section 2. Representative agarose gels of amplified DNA are shown. GAPDH
amplification was used for data normalization. (b and d) Quantification of mRNA expression by real-time PCR analysis. Data are reported
as mean± S.E.M. of the ratio between the fold of variation of S1P receptor expression obtained from high- and low-density BM-MSCs
culture. (e and f) BM-MSCs seeded onto fluorescein-labeled gelatin substrate- (DQ gelatin-) coated plastic culture plates (e) or glass
coverslips (f) were cultured for 48 h in absence (vehicle) or in presence of the following compounds: 5μM sphingosine kinase inhibitor
(iSK), 1μM exogenous sphingosine-1-phosphate (exoS1P), 2μM S1PR1 receptor antagonist, W146, and 2 μM S1PR1 receptor agonist,
SEW2871. (e) Spectrophotometrical quantification of the DQ gelatin fluorescence intensity revealed after proteolytic digestion of the
gelatin by MMP gelatinases. (f) Representative superimposed DIC (grey) and fluorescent confocal microscopy images (green; gelatin
fluorescence intensity) of fixed cells. Scale bar 30μm. Histogram shows the densitometric analysis of the intensity of the gelatin
fluorescence signals performed on digitized images. Data reported as mean± S.E.M. are representative of at least three independent
experiments with similar results. Significance of differences in (b) and (d) (Student’s t-test), ∗p < 0 05 and ∗∗p < 0 01; in (e) and
(f) (one-way ANOVA and Newman-Keuls multiple comparison test), ∗p < 0 05 versus vehicle, °p < 0 05 versus SEW2871.
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cultured in the presence of exoS1P exhibited a significant
increase of MMP-2 expression, as compared to control cells
(Figures 2(a) and 2(b)). W146 promoted a robust downregu-
lation of the enzyme expression (Figures 2(a) and 2(b)), asso-
ciated with a reduction of the release of MMP-2 active form,
as judged by zymography (Figure 2(c)), further underlying
the role of S1PR1-mediated signalling in the control of
ECM remodelling. The treatment of the cells with
SEW2871 was not able to modify MMP-2 expression
(Figures 2(a) and 2(b)) and activity (Figure 2(c)) as compared
to control.
3.3. S1PR1/MMP-2 System Affects Plasma Membrane-
Associated F-Actin Structures and Cell Proliferation in BM-
MSCs. It has been demonstrated that MMPs are required
for actin filament polymerization (F-actin) and cytoskele-
ton assembly in many cell types [8]. Thus, we analysed
the actin cytoskeleton organization in BM-MSCs treated
with exoS1P and S1PR1 ligands. The observation at confo-
cal fluorescence microscope revealed that control cells have
a polygonal appearance with actin filaments parallelly
arranged, principally at the cell periphery, consistent with
lamellipodia-like structures. Some cells also displayed
actin-rich plasma membrane protrusions, such as filopodia
and small punctate structures (microspikes) (Figure 3(a)).
Moreover, the confocal immunofluorescence analysis of the
expression of cortactin, amultidomain protein known to con-
tribute to the formation of dynamic cortical actin-associated
structures (such as lamellipodia) as well as to the transduction
of specific cell signalling [54–56], revealed that this protein
was diffused throughout the cytoplasm and, in some cells,
colocalized with cortical F-actin at the cell periphery
(Figures 3(a) and 3(i); overlap coefficient r: 0.924± 0.055).
The cells treated with exoS1P showed actin-rich plasma
membrane protrusions concomitantly with a robust increase
of cytoskeleton assembly as compared to control cells,
consisting in the formation of well-structured F-actin fila-
ments spanning through the length of the cell (Figure 3(b))
according to previous reports [35] and cortactin appeared
mainly cortically localized (Figures 3(b) and 3(i)). In
these cells, no differences in cortactin expression and
colocalization degree with F-actin (overlap coefficient r:
0.817± 0.11, p > 0 05 versus vehicle) were found as compared
to control cells.
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Figure 2: MMP-2 expression and activity. BM-MSCs were cultured for 48 h in the absence (vehicle) or in presence of 1 μM exogenous
sphingosine-1-phosphate (exoS1P) or 2μM S1PR1 receptor antagonist, W146, or 2 μM S1PR1 receptor agonist, SEW2871. (a)
Representative immunofluorescence confocal images of fixed cells on glass coverslips immunostained with antibodies against MMP-2
(green). Scale bar 50 μm. The images are representative of at least three independent experiments with similar results. (b) Densitometric
analysis of the intensity of the MMP-2 fluorescence signal performed on digitized images. (c) Zymography. A representative gelatin
zymography of MMP-2 from conditioned media obtained from BM-MSCs incubated in absence (vehicle) or in presence of W146 or
SEW2871 for 48 h. Densitometry scanning from at least three separate experiments was performed and data, expressed as relative OD
values (a.u.) to those of control group (vehicle) set to 100, are reported in the histogram. Data are mean± S.E.M. Significance of difference
in (b) (one-way ANOVA and Newman-Keuls multiple comparison tests), ∗p < 0 05 versus vehicle, °p < 0 05 versus SEW2871; in (c)
(Student’s t-test), ∗p < 0 05 versus vehicle.
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Figure 3: Cytoskeleton organization and cortactin expression. BM-MSCs were cultured for 48 h in the absence (vehicle) or in presence of the
following compounds: 1μM exogenous sphingosine-1-phosphate (exoS1P), 2μM S1PR1 receptor antagonist, W146, and 2μM S1PR1
receptor agonist, SEW2871 and/or MMP-2/9 inhibitor, SB-3CT (5 μM or 10 μM). (a–h) Representative immunofluorescence confocal
images of cells cultured on glass coverslips in the indicated experimental conditions, fixed and stained with Alexa 568-phalloidin to
visualize actin filaments (red) and immunostained with antibodies against cortactin (green). Scale bar 50μm. Arrows indicate filopodia
and arrowheads indicate lamellipodia (L). (A–D) Magnifications of the indicated squared regions of interest showing the red and green
fluorescence signals separately and together. Yellow-orange colour indicates colocalization between the two fluorescence signals. Scale bar
12μm. The images are representative of at least three independent experiments with similar results. (i) Densitometric analysis of the
intensity of the cortactin fluorescence signal performed on digitized images. Data are mean± S.E.M. Significance of differences (one-way
ANOVA and Newman-Keuls multiple comparison test): ∗p < 0 05 versus vehicle, °p < 0 05 versus SEW2871.
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Of note, W146-treated cells showed a more elongated
shape, a marked reduction of F-actin assembly and the
disappearance of the membrane protrusions associated
with a reduction of cortactin expression as compared
to control cells (Figures 3(c) and 3(i); overlap coefficient
r: 0.922± 0.054, p > 0 05 versus vehicle). The F-actin
assembly and cell shape in BM-MSCs treated with
SEW2871 were comparable to those of control cells
(Figure 3(d)) as well as cortactin expression/distribution
(Figures 3(d) and 3(i); overlap coefficient r: 0.923± 0.06,
p > 0 05 versus vehicle).
To further evaluate the involvement of MMP-2 on the
cytoskeletal remodelling triggered by S1PR1 activation, we
analysed F-actin assembly and cortactin expression of the
cells treated with a specific inhibitor of MMP-2/9 and SB-
3CT (5 and 10μM) in absence or presence of SEW2871.
We found that BM-MSCs treated with SB-3CT alone
(Figures 3(e), 3(f), and 3(i)) showed a cytoskeletal disassem-
bly, peripheral cortactin expression reduction, and a mor-
phology similar to those of cells treated with W146
(Figures 3(c) and 3(i)). The effects elicited by the combined
treatment with SB-3CT and SEW2871 (Figures 3(g)–3(i))
were not different from those induced by SB-3CT alone
(Figures 3(e), 3(f), and 3(i)).
Altogether, these data suggest that the activation of
MMP-2 through S1PR1-mediated signalling is required
for plasma membrane-associated F-actin structures in
BM-MSCs.
It has been reported that plasma membrane-associated F-
actin structure formation can affect cell proliferation [57–60].
Thus, we evaluated the involvement of S1PR1-triggered sig-
nalling on BM-MSCs in this biological process. The results
indicate that the expression of nuclear Ki67, a specific marker
of cell division, appeared reduced by approximately 30%
ratio in the presence of W146 with respect to control after
24 h culture, whereas the treatment with SEW2871 was not
effective (Figure 4(a)). Similar data were also obtained when
proliferation was assessed by cell counting (Figure 4(b)).
Notably, the reduced cell proliferation observed in the
presence of W146 was not due to cell toxicity. In fact, the
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Figure 4: Cell proliferation and toxicity. BM-MSCs were incubated in growth medium for 24 h in absence (vehicle) or in presence of 1μM
exogenous sphingosine-1-phosphate (exoS1P), 2 μM S1PR1 receptor antagonist, W146, or 2 μM S1PR1 receptor agonist, SEW2871. (a)
Representative confocal immunofluorescence images of Ki67 expression. BM-MSCs were immunostained with the specific antibody Ki67
(green), a nuclear proliferation marker, and counterstained with propidium iodide (PI; red). Yellow colour indicates colocalization of red
and green fluorescence signals. Scale bar 50 μm. The images are representative of at least three independent experiments with similar
results. Histogram represents quantitative analysis of Ki67 positive BM-MSC cell nuclei expressed as percentage of the total nuclei
number. Data are mean± S.E.M. (b) Cell proliferation analysis by cell counting. Synchronized BM-MSCs were collected and counted as
reported in Section 2. Data are mean± S.E.M. of four independent experiments performed in quadruplicate. (c) Western blotting analysis
of apoptotic (Bax) and autophagic (Beclin) markers. Cell lysates (10–25 μg) obtained from BM-MSCs were loaded onto SDS-PAGE and
proteins immunodetected by specific antibodies. β-Actin was used as loading control. Blot shown is representative of at least three
independent experiments with similar results. Data resulting from densitometric analysis of at least three independent experiments are
shown in the graph (mean± S.E.M.). Significance of differences in (a) and (b) (one-way ANOVA and Newman-Keuls multiple
comparison test): ∗p < 0 05 versus vehicle.
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levels of the expression of the proapoptotic marker, Bax, and
of the autophagic marker, Beclin, were no different in the
presence of S1PR1 antagonist with respect to control or
SEW2871 (Figure 4(c)).
Finally, the treatment with exoS1P did not affect cell pro-
liferation consistently with cytoskeleton assembly observed
in S1P-stimulated cells (Figures 4(a) and 4(b)), and sug-
gesting that S1PR1 and the other S1PR subtypes, activated
by exoS1P, are differently involved in the modulation of
BM-MSC responses (namely, ECM remodelling, actin
assembly, and cell proliferation).
3.4. S1PR1 Affects Stress Fiber Formation in BM-MSCs
Cultured in Hypoxic Conditions. In order to mimic the
hypoxic microenvironment occurring in a damaged/regener-
ating tissue, parallel experiments were performed by cultur-
ing BM-MSCs in low oxygen conditions (2%). First, we
evaluated by confocal immunofluorescence and Western
blotting analyses the expression of HIF-1α, the oxygen-
regulated subunit of the heterodimeric transcription factor
HIF, which directs the transcriptional responses to hypoxia
[61]. As expected, we found that BM-MSCs showed a signif-
icantly higher expression of HIF-1α, either in the cytoplasm
and in the nucleus, as compared to the control cells cultured
under normoxia (Figures 5(a) and 5(b)). In normoxia, HIF-
1α was barely detected in all experimental conditions and
no differences were observed among control, W146- and
SEW2871-treated cells. Similarly, Western blotting analysis
showed that the expression level of HIF-1α in W146-
treated cells under hypoxia was significantly reduced of about
30%, whereas in SEW2871-treated cells, the protein content
was similar to that of control cells (Figure 5(c)).
These findings are the first evidence that S1PR1-
mediated signalling plays a crucial role in the control of
HIF-1α expression in BM-MSCs under hypoxia.
As judged by confocal immunofluorescence analysis
and zymography, the cells under hypoxia showed reduced
MMP-2 expression (Figures 6(a) and 6(b)) and activity
(Figure 6(c)) as compared to normoxia (Figure 2) and
W146 treatment, differently to SEW2871, further decreased
MMP-2 expression. These findings suggest that MMP-2
expression/activity is negatively affected by hypoxic condi-
tions in BM-MSCs.
The morphological analysis revealed that the cells in
hypoxia appeared more elongated and did not present the
plasma membrane-associated F-actin structures (Figure 7(a),
A), as observed in normoxia (Figure 3). In addition, the
vehicle- and SEW2871-treated cells showed well-organized
F-actinfilaments (stressfibers), spanning parallel to the length
of the cells (Figure 7(a), A–C) and a weak staining of cor-
tactin (Figure 7(a), A, C, and G) which, however, appears
to be colocalized with cortical actin (overlap coefficient r:
vehicle, 0.922± 0.064; SEW2871, 0.919± 0.064, p > 0 05 ver-
sus vehicle). By contrast, as compared to control cells,
W146-treated cells under hypoxia displayed a reduction of
stress fiber assembly and of the expression of cortactin
(Figure 7(a), B and G; overlap coefficient r: vehicle, W146,
0.944± 0.066, p > 0 05 versus vehicle). Of note, these cells
showed an upregulation of the expression levels of vinculin,
a focal adhesion protein involved in cell/matrix connection
[62] (Figure 7(a), D, F, and H), suggesting that W146 treat-
ment is not toxic but that the inhibition of S1PR1 signalling
might act as a cell fate determinant. Consistent with these
morphological features, cell proliferation was reduced in
hypoxia as compared to normoxia and, in the same experi-
mental conditions, W146 treatment further decreased cell
number (Figure 7(b)).
Altogether, these data suggest that S1PR1-mediated
signalling in hypoxic conditions is required for HIF-1α and
MMP-2 expression/activity, cortactin expression, and reduc-
tion of vinculin expression as well as stress fiber formation
and cell proliferation.
4. Discussion
MMP-2 preferentially degrading collagen and gelatin plays
an important role in BM-MSC migration [14, 46, 47, 63]
and in cell proliferation [64–66]. It has been also reported
that MMPs can rapidly act on several specific substrates
inside the cells, such as cytoskeleton and cytoskeleton-
associated proteins [8, 67–69]. Therefore, the identification
of physiological regulators of the MMP-2 function is of great
biological relevance in BM-MSC field and could offer clues to
improve their therapeutic efficacy. In such a view, our data
appear intriguing and of potential clinical interest. In fact,
here, we demonstrate, for the first time, the trophic role
exerted by the signalling pathways downstream to the activa-
tion of S1PR1 in the modulation of the MMP-2 gelatinolytic
activity and substantial cytoskeleton remodelling. In fact, we
found that cells in normoxic conditions treated with S1PR1
antagonist W146 showed a reduction of MMP-2 expres-
sion/activity as well as of F-actin assembly and the
disappearance of plasmamembrane-associated F-actin struc-
tures, such as lamellipodia-like structures, filopodia, and
small punctate structures (microspikes) associated with a
decrease of cortactin expression, similarly to the cells treated
with a specific MMP inhibitor. In addition, under hypoxic
conditions the cells with blocked S1PR1 showed an upregula-
tion of vinculin.
The observed lack of effects of S1PR1 agonist SEW2871
may suggest that the signalling pathways, mediated by
S1PR1 and leading to MMP-2 activation, actin cytoskeleton
reorganization and ECM remodelling, are already maximally
activated by the presence of either endogenously released
S1P. These data contribute to further suggest that the sig-
nalling pathway downstream of S1PR1 is constitutively
activated by the endogenously formed and released S1P
and it is a trophic response; in fact, only a downregulation
of the receptor is able to perturb the BM-MSC response.
The involvement of other S1P receptor subtypes in medi-
ating ECM remodelling, as reported in other studies, cannot
be excluded [70–72]. Accordingly, in this study, we demon-
strated that exoS1P is able to upregulate MMP-2 expression
and promote actin assembly. Experiments are ongoing in
our lab to deeply analyse the involvement of the other recep-
tor subtypes. However, our preliminary results indicate that
S1PR2 antagonist is not effective in regulating MMP-2
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Figure 5: HIF-1α expression. BM-MSCs were cultured for 48 h in normoxic or in hypoxic conditions in the absence (vehicle) or in presence
of 2 μM S1PR1 receptor antagonist, W146, or 2 μM S1PR1 receptor agonist, SEW2871. (a) Representative immunofluorescence confocal
images of cells cultured on glass coverslips in the indicated experimental conditions, fixed and immunostained with antibodies against
HIF-1α (green). Scale bar 50μm. The images are representative of at least three independent experiments with similar results. (b)
Densitometric analysis of the intensity of the HIF-1α fluorescence signal performed on digitized images. Data are mean± S.E.M. (c)
Western blotting analysis of HIF-1α. Cell lysate (30 μg) obtained from BM-MSCs cultured in hypoxia and treated as reported above was
loaded onto SDS-PAGE and protein immunodetected by a specific antibody. β-Actin was used as loading control. Blot shown is
representative of at least three independent experiments with similar results. Data resulting from densitometric analysis of at least three
independent experiments is shown in the graph (mean± S.E.M.). Significance of differences in (b) (one-way ANOVA and Newman-Keuls
multiple comparison test), ∗p < 0 05 versus normoxia, °p < 0 05 versus vehicle hypoxia; in (c) (Student’s t-test), ∗p < 0 05 versus vehicle.
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activity in BM-MSCs, whereas a specific antagonist of S1PR3
is not commercially available.
The relationship between MMP inhibition and reduction
of cytoskeleton assembly [8] and the ability of the S1P signal-
ling to regulate MMP-2 [17, 34, 35, 48, 49] and ECM remod-
elling [73, 74] are consistent with previous reports in
different cell types. Moreover, our findings are also in accor-
dance with the observation that the S1P/S1PR1 axis is able to
stimulate, through the activation of Cdc42/Rac pathway, the
translocation of cortactin towards the cell periphery, where
the cortical actin contributes to form lamellipodia [75]. Thus,
it can be supposed that S1P/S1PR1/MMP-2 system may have
a similar function in BM-MSCs. On the other hand, since it
has been demonstrated that cortactin is an essential regulator
of MMPs [76, 77], we can also speculate that S1PR1 signal-
ling may modulate MMP-2 expression/activity via regulation
of cortactin expression.
A further intriguing result of this study is the autocrine
action of S1P released by BM-MSCs via S1PR1. In fact, both
the inhibition of SphK activity and the blockade of S1PR1
strongly affect ECM remodelling and MMP-2 activation.
The novelty and the importance of these findings rely on
the fact that the autocrine/trophic role of the endogenously
formed and released bioactive lipid S1P would make BM-
MSCs less dependent on a niche created by other cells types
underlying also the relevance of a specific S1PR subtype in
such action.
Furthermore, our data represent the first evidence of a
change in the expression level of S1P receptor subtypes in
stem cells with a predominance of S1PR1 expression in
high-density BM-MSC culture. These data may contribute
to further suggest the potentiality of MSCs to modulate their
own constitutive responses by this molecular mechanism,
independently from extracellular signals.
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Figure 6: MMP-2 expression and activity in MSCs cultured under hypoxic conditions. BM-MSCs were cultured for 48 h under hypoxic
conditions in the absence (vehicle) or in presence of 2 μM S1PR1 receptor antagonist, W146, or 2μM S1PR1 receptor agonist, SEW2871.
(a) Representative immunofluorescence confocal images of cells cultured on glass coverslips, fixed and immunostained with antibodies
against MMP-2 (green). Scale bar 50 μm. The images are representative of at least three independent experiments with similar results. (b)
Densitometric analysis of the intensity of the MMP-2 fluorescence signal performed on digitized images. Data are mean± S.E.M. (c)
Zymography. A representative gelatin zymography of MMP-2 from conditioned media obtained from BM-MSCs incubated in the absence
(vehicle) or in the presence of 2μM S1PR1 receptor antagonist, W146, or 2 μM S1PR1 receptor agonist, SEW2871, for 48 h. Densitometry
scanning from at least three separate experiments was performed and data, expressed as relative OD values (a.u.) to those of the control group
(vehicle) set to 100, are reported in the histogram. Data are mean± S.E.M. Significance of differences in (b) and (c) (Student’s t-test): ∗p < 0 05
versus vehicle.
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Figure 7: Cytoskeleton organization, cortactin and vinculin expression, and cell proliferation in BM-MSCs cultured under hypoxic
conditions. (a, A–F) Representative immunofluorescence confocal images of BM-MSCs cultured on glass coverslips for 48 h under hypoxic
conditions in the absence (vehicle) or in the presence of 2μM S1PR1 receptor antagonist, W146, or 2 μM S1PR1 receptor agonist,
SEW2871, fixed and stained (A–C) with Alexa 568-phalloidin to detect actin filaments (red) and immunostained with antibodies against
cortactin (green) and (D–F) with antibodies against vinculin (cyan). Scale bar 50 μm. The images are representative of at least three
independent experiments with similar results. (a, G and H) Densitometric analyses of the intensity of the (G) cortactin and (H) vinculin
fluorescence signals performed on digitized images. Data are mean± S.E.M. (b) Cell proliferation analysis by cell counting. Synchronized
BM-MSCs were incubated in growth medium for 48 h in normoxia and hypoxia (histogram on left) or in hypoxia in the absence (vehicle)
or in presence of 2 μM S1PR1 receptor antagonist, W146, or 2μM S1PR1 receptor agonist, SEW2871 (histogram on the right). Cells were
collected and counted by TALI Cytometer as reported in Section 2. Data are mean ± S.E.M. of four independent experiments performed
in quadruplicate. Significance of differences in (a) (G and H, Student’s t-test), ∗p < 0 05 versus vehicle; in (b) (Student’s t-test), ∗p < 0 05
versus normoxia or vehicle.
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High- and low-density BM-MSC culture can be consid-
ered to reflect the behaviour of BM-MSCs in vivo; indeed, it
appears conceivable that BM-MSCs, which are rarefied
in vivo (low density) in a normal/physiological tissue, display
a higher degree of aggregation (high density) in a damaged
tissue. It has been reported that many biological activities of
MSCs could be influenced by the confluence of the cells
[78]. For instance, a density-dependent behaviour of MSCs
has been reported in the study by Lapi et al. [79], showing
that the addition of hEGF to MSC culture is more efficient
in promoting self-renewal in low-density versus high-
density culture, indicating the requirement of specific
signalling pathways in the two different conditions. In
addition, it shall be considered that, in order to contribute
to tissue repair, the cells need to be protected either
against differentiation signals and apoptosis as well as to
undergo proliferation before reaching the injury sites where
they accumulate. After that, they presumably could switch
cell program, stopping the self-renewal and the proliferation
program and starting the commitment. Therefore, the novel
finding of a significant increase in the content of S1PR1 in
high-density culture might indicate a potential role of
S1PR1-mediated signalling in the downregulation of self-
renewal ability and/or, likely, promotion of cell prolifera-
tion/commitment. Further investigations are ongoing in
our laboratory to address this topic. However, our reported
finding that S1PR1 antagonist reduces cell proliferation and
promotes cell growth arrest, but not the expression of apo-
ptotic or autophagic markers, indicates the role of S1PR1-
mediated signalling in the control of BM-MSC cell cycle.
Moreover, our findings may support that S1PR1 sig-
nalling can modulate cell proliferation via MMP-2 and
cytoskeleton remodelling in BM-MSCs. In fact, it has been
reported that (i) MMP-2 expression regulates MSC prolifer-
ation [64–66]; (ii) the actin cytoskeleton structure determines
cell shape and the cytoskeleton-dependent cell morphology
affects cell proliferation, in particular, actin-rich plasma
membrane-associated structures, such as filopodia and
small punctate structures (microspikes), are suggestive of
cell spreading and that cells unable to spread show a reduced
proliferation [57–60]; and (iii) cortactin, beside its role as
a molecular scaffold for the formation of dynamic cortical
actin-associated structures, has been shown to modulate
specific molecular signalling targets involved in cell
proliferation (e.g., ERK1/2) [56, 80]. Therefore, it is
possible to speculate that the increase in S1PR1 expression
in high-density BM-MSC culture is needed to prompt
cortactin expression/MMP-2 activity and, likely, cell prolif-
eration ability, by inducing changes in cell morphology
and cytoskeletal organization.
In this study, we also found that S1PR1-mediated signal-
ling plays a crucial role in BM-MSCs cultured under hypoxic
conditions which resemble the microenvironment of dam-
aged/repairing tissue. Moreover, since in literature hypoxia
reduces the proliferative potential of BM-MSCs concomi-
tantly to an enhancement of cell differentiation [81], our
findings show that the S1PR1 antagonist reduces HIF expres-
sion may support the role of S1PR1 in the regulation of HIF-
1α. In addition, since the stabilization of HIF-1α leads to
cell cycle arrest in response to hypoxia in various cell
types [82], the regulation of the expression of this tran-
scriptional factor and its nuclear localization support the
role of S1PR1-mediated signalling also in cell proliferation
regulation under hypoxia. Many studies on the biologic
activity of BM-MSCs have produced contradictory results
regarding up- or downregulation of proliferation or differ-
entiation of BM-MSCs [83–85] as well as the expression of
MMP-2 in MSCs in hypoxia [86]; this could be dependent
on the differences in the hypoxic conditioning protocols
among the various studies, making comparison difficult.
In any case, many of the cellular responses to reduced
oxygen availability are mediated by the transcriptional
activity of HIF-1 [61] and, accordingly, our results showed
a significant increase in the expression level of this factor
in the cells under hypoxia.
Our data concerning proliferation are in agreement with
recent findings establishing a transcription-independent
mechanism by which the stabilization of HIF-1α leads to cell
cycle arrest in response to hypoxia in various cell types [82].
Of note, the finding reported in this study that the S1PR1
antagonist reduces HIF-1α expression and its nuclear locali-
zation suggests that S1PR1-mediated signalling could be
required to maintain the expression/activity of HIF-1α under
hypoxia, which contributes in supporting the previous find-
ings of the role for S1P as a regulator of this transcriptional
factor [87]. Interestingly, the S1PR1/HIF-1α system may be
required to regulate F-actin assembly into stress fibers that
we observed in the cells under hypoxia. It has been, in fact,
demonstrated that HIF-1 regulates cytoskeletal reorganiza-
tion, consisting mainly in stress fiber formation in different
cell types by activating RhoA [88] as it has been shown also
for S1P [35, 89]. Therefore, considering that RhoA negatively
affects MMP-2 [90], we can speculate that S1PR1-mediated
signalling may be important to maintain HIF-1α function
which, in turn, upregulates RhoA; this event could downreg-
ulate MMP-2 and promote the formation of stress fibers. The
appearance of stress fibers in hypoxia, concomitantly with
the disappearance of the plasma membrane-associated F-
actin structures, changes in cell shape from polygonal to
elongated, and the reduction of cell proliferation were
suggestive of an enhanced cell adhesion.
Finally, the upregulation of vinculin observed under hyp-
oxia in the presence of the S1PR1 antagonist may suggest the
role for S1PR1-mediated signal in contributing to downregu-
late vinculin which, besides its role as a force-sensitive adhe-
sion protein, has been proved to be able to modulate the
differentiation of BM-MSCs [62].
5. Conclusion
In this study, we demonstrated for the first time the trophic
constitutive role exerted by the signalling pathways down-
stream of S1PR1 in maintaining the ability of BM-MSCs to
modulate MMP-2 expression/activity, important for remod-
elling the surrounding ECM and reorganizing actin cytoskel-
eton in order to regulate cell proliferation (Figure 8).
Our findings may open new windows for a smart target-
ing of S1PR1 for the application in cell therapy, by preserving
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BM-MSC properties and potentiating their efficacy for tissue
repairing purposes.
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